References
- Observatory Global Cancer. GLOBOCAN 2020. Published 2022. 2022 Apr 20. Available from: https://gco.iarc.fr/today.
- Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–892. doi:https://doi.org/10.1016/j.euo.2021.09.006.
- Li J, Cai Z, Wei W, Wang X, Peng X. Establishment of prognostic nomograms for early-onset prostate cancer patients: a SEER database analysis. J Investig Surg. 2022:1–10. doi:https://doi.org/10.1080/08941939.2022.2062495.
- Morlacco A, Modonutti D, Motterle G, Martino F, Dal Moro F, Novara G. Nomograms in urologic oncology: lights and shadows. JCM. 2021;10(5):980. doi:https://doi.org/10.3390/jcm10050980.
- Castellani D, Cecchini S, Mazzucchelli R, et al. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy. Urol Oncol Semin Orig Invest. 2022. Online ahead of print.
- Radtke JP, Wiesenfarth M, Kesch C, et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol. 2017;72(6):888–896. doi:https://doi.org/10.1016/j.eururo.2017.03.039.
- Bandini M, Fossati N, Briganti A. Nomograms in urologic oncology, advantages and disadvantages. Curr Opin Urol. 2019;29(1):42–51. doi:https://doi.org/10.1097/MOU.0000000000000541.
- Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: Preoperative application in prostate cancer. Curr Opin Urol. 2003;13(2):111–116. doi:https://doi.org/10.1097/00042307-200303000-00005.
- Hu Y, Qi Q, Zheng Y, et al. Nomogram for predicting the overall survival of patients with early-onset prostate cancer: a population-based retrospective study. Cancer Med. 2022. doi:https://doi.org/10.1002/cam4.4694.